• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MyMD Pharmaceuticals Inc. (Amendment)

    2/23/22 4:45:14 PM ET
    $MYMD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYMD alert in real time by email
    SC 13G/A 1 c103102_sc13ga.htm
     
         
      SECURITIES AND EXCHANGE
    COMMISSION
     
      Washington, D.C. 20549  

     

         

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 3)*

     

    MyMD Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, no par value per share

    (Title of Class of Securities)

     

    62856X102

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    o Rule 13d-1(d)

     

         

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

         

     

     CUSIP No: 62856X102
      (1) Names of Reporting Persons
    Iroquois Capital Management L.L.C.
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6)

    Shared Voting Power
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

     
    (7) Sole Dispositive Power
    0
     
    (8)

    Shared Dispositive Power
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
      (11) Percent of Class Represented by Amount in Row (9)
    3.66%
      (12) Type of Reporting Person (See Instructions)
    OO

     

    CUSIP No: 62856X102
      (1) Names of Reporting Persons
    Richard Abbe
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power
    1,918,242 shares of Common Stock

    409,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     
    (6)

    Shared Voting Power
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     
    (7)

    Sole Dispositive Power
    1,918,242 shares of Common Stock

    409,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     
    (8)

    Shared Dispositive Power
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    2,178,608 shares of Common Stock

    1,568,044 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
      (11) Percent of Class Represented by Amount in Row (9)
    9.56%
      (12) Type of Reporting Person (See Instructions)
    IN; HC

     

     CUSIP No: 62856X102
      (1) Names of Reporting Persons
    Kimberly Page
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6)

    Shared Voting Power
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     
    (7) Sole Dispositive Power
    0
     
    (8)

    Shared Dispositive Power
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    260,366 shares of Common Stock

    1,158,299 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
      (11) Percent of Class Represented by Amount in Row (9)
    3.66%
      (12) Type of Reporting Person (See Instructions)
    IN
     

    CUSIP No: 62856X102

    This Amendment No. 3 (this “Amendment”) amends the statement on Schedule 13G filed on December 18, 2019 and amended on November 19, 2020 and February 22, 2021 (the “Original Schedule 13G”) with respect to the Common Stock, $0.001 par value (the “Common Stock”) of MyMD Pharmaceuticals, Inc. (previously named Akers Biosciences, Inc.) (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment amends and restates Item 4 in its entirety as set forth below.

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 37,639,912 shares issued and outstanding as of November 12, 2021 as reported by the Issuer in its Quarterly Report on Form 10-Q/A for the quarter ended September 30, 2021, filed by the Issuer with the SEC on November 15, 2021, and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”), subject to the Blockers (as defined below).

     

    Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (collectively, the “Blockers”), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held 260,366 shares of Common Stock and Reported Warrants to purchase 1,158,299 shares of Common Stock and Iroquois Capital Investment Group LLC (“ICIG”) held 1,918,242 shares of Common Stock and Reported Warrants to purchase 409,745 shares of Common Stock. In addition, each of The Samantha Abbe Irrevocable Trust, The Talia Abbe Irrevocable Trust, The Bennett Abbe Irrevocable Trust and the Abbe Berman Foundation held 38,590, 38,590, 38,590 and 49,110 shares of Common Stock, respectively,

     

    Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by and underlying the Reported Warrants (each subject to the Blockers) held by, Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of ICIG. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by and underlying the Reported Warrants (each subject to the Blockers) held by, Iroquois Master Fund and ICIG. In addition, by virtue of his position as a custodian or trustee of certain Accounts (The Samantha Abbe Irrevocable Trust, The Talia Abbe Irrevocable Trust and The Bennett Abbe Irrevocable Trust), Mr. Abbe may be deemed to be the beneficial owner of the 115,770 shares of Common Stock held in aggregate by such Accounts. In addition, by virtue of his position as trustee of the Abbe Berman Foundation, Mr. Abbe may be deemed to be the beneficial owner of the 49,110 shares of Common Stock held by the Abbe Berman Foundation. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of Iroquois Master Fund and Mr. Abbe and Ms. Page hereby disclaims any beneficial ownership of any such shares of Common Stock. The amounts shown as beneficially owned do not include 112,270 shares of Common Stock held by The Merav Abbe Trust as Mr. Abbe does not have voting or dispositive control over those shares. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 22, 2022

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.
           
      By:  /s/ Richard Abbe  
               Richard Abbe, President  
           
        /s/ Richard Abbe  
      Richard Abbe  
           
        /s/ Kimberly Page  
      Kimberly Page  
     
    Get the next $MYMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MYMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MYMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today

      New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat

      7/24/24 9:05:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

      New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com

      7/22/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

      MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. "I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms," stated David Rini. David Rini is a Professor at the Johns Hopkins University School of Medicine in the Department of Art of Applied to Medicine, Cellular and Molecular Medicine, and Director of the Medical and Biological Illustration Graduate Program. Professor Rini earned his M

      5/17/21 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Financials

    Live finance-specific insights

    See more
    • MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

      MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w

      8/2/23 8:30:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

      - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica

      7/31/23 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by MyMD Pharmaceuticals Inc.

      SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      5/30/24 4:05:03 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by MyMD Pharmaceuticals Inc.

      SC 13G - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 3:13:35 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by MyMD Pharmaceuticals Inc. (Amendment)

      SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 11:27:33 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    SEC Filings

    See more
    • SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.

      DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      7/1/24 5:15:16 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/24/24 4:23:01 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-3 filed by MyMD Pharmaceuticals Inc.

      S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/21/24 5:14:29 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Friscia Stephen

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      6/28/24 4:05:18 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Pharmacyte Biotech, Inc.

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/30/24 4:05:04 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Glass Mitchell

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/16/24 5:30:25 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care